Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: Belongs to BIMINI

Belongs to BIMINI 28 Mar 2014 17:28 #1458

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 385
  • Thank you received: 196
Came across this video that refers to PUREGRAFT, a successful product that has been sold by Cytori and which is hopefully making more plastic surgeons aware of Cytori, even if only indirectly.

Don't watch this video if you are squimish. :puke: My initial take is that if someone wants to go through this procedure for the sake of beauty/vanity then at least let them have the benefit of ADRC enhanced fat grafting. I personally would not have to want to go through this again due to fat absorption. ADRC/Fat banking of course may alleviate the need for additional lipo but it does not cover the need for touch ups if absorption occurs.

feedtheagency.com/project/surgical-on-demand-webinar-video/

Fascinating that you can undertake a medical procedure like this but cannot have additional autologous ADRC cells added to the graft. Pure homologous autologous procedure ...... irrational that it cannot be used. A blind FDA alley that Cytori entered ............ but a reasonable and rational choice at the time. :cry:
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Belongs to BIMINI 28 Mar 2014 21:25 #1459

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 385
  • Thank you received: 196
We have some further proof of the validity in using ADRC for breast reconstruction from Copenhagen.

www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61410-5/abstract

The only thing wrong with their trial is that they should have had an additional arm (no pun intended) that included a Celution processed, real time ADRC augmented fat graft.

If the results were comparable to the expanded cell graft then the cost benefit analysis would certainly come into play......... two lipos and manual cell processing and cell expansion vs Celution ..... it's a no brainer. :bash:

Lets hope that the Danes are more compassionate than the British towards woman who have suffered from cancer surgery, and use their results to push forward for reimbursement in breast reconstruction............. the question is how passionate are researchers in the acceptance/commercialisation of their research ?? In the end I fear it will need patients being made aware that there is way to repair lumpectomy defects ........ Pissed off women may be a positive.......... perhaps I should send all this stuff we find to the Susan Komen organisation ....... they're big, international and connected. :write:
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Belongs to BIMINI 29 Mar 2014 12:39 #1460

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3333
  • Thank you received: 1115

perhaps I should send all this stuff we find to the Susan Komen organisation ....... they're big, international and connected.


Sometimes I think Cytori needs some help from their friends, since they appear not to do the obvious most of the time.. :whistle:

Anyway- your posts on the subject of breast reconstruction kind of took me on a trip to memory lane and for that reason, you might want to be made aware of facts on some of the stops down this "lane".... :winky:

First- the link to the video brings one to the Feedtheagency site, which has long been the "art" provider for Cytori for the promotion campaigns. Former Cytori employees- Matthew Scott (former social media director) and Bruce Reuter (former VP Global Marketing) are employed there now as far as I know.

The guy introducing Dr. Cohen- Brad Conlan- now Bimini CEO- of course is ex-Cytori also. You can read his LinkedIn profile here-

Brad Conlan Profile

From this profile - two things Brad was responsible for for about 18 months-

Olympus Corporation:
* Licensing of Gastro-Intestinal Regenerative Medicine Indication
Astellas Pharma:
* Licensing of Liver Disease Regenerative Medicine Indication


The above means that everything on this site about Olympus is correct.
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Belongs to BIMINI 29 Mar 2014 17:49 #1461

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2820
  • Thank you received: 201
The Olympus and Astellas history is clear...question is where are they now ?? !!!!!!!

Please Log in or Create an account to join the conversation.

Belongs to BIMINI 29 Mar 2014 21:34 #1462

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 385
  • Thank you received: 196
Fas, I am not sure what your comment alluded to when you stated: "The above means that everything on this site about Olympus is correct."

What I do know is that CYTX has been given CE approval for wound healing and specifically Crohn's fistula, an approval I might add that others are still working towards. You are absolutely right to be incredulous of the current state of affairs. Here we have a management that has signed away China and a large part of Asia for all indications and yet has not managed to progress the marketing of Celution in an indication that is approved and where there is a clear clinical need. I appreciate the need for funding, and can imagine the difficulties in accessing a market like China. What I cannot understand is why something cannot be done in Europe with some of the ALREADY APPROVED indications.

The secrecy concerning the data that led to these approvals is also incomrehensible and UNACCEPTABLE. Their fear of being wrong with regard guidance, as in the past, concerning partnership deals is understandable, but now we have gone to the other extreme.

Management has a fiduciary responsibility to act in our best interests. We do not expect to be privy to the minutae of negotiations .......... but I am tired of being treated like a mushroom. :evil: :bash:

Astellas has been privy to our BoD, technology and management for a very long time. An indication that they are still working towards a deal in Liver indications would be most appreciated. Surely they have some human clinical data by now. :really: :really:
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Belongs to BIMINI 30 Mar 2014 07:19 #1463

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3333
  • Thank you received: 1115

Fas, I am not sure what your comment alluded to when you stated: "The above means that everything on this site about Olympus is correct."


John- actually I specifically refer to the first part of the Olympus relation- i.e. the 2005 manufacturing deal. There are many folks who still see the Olympus relation as "pure manufacturing" which is totally wrong. The manufacturing was simply part of the gastro- therapeutic plans of Olympus, which I understood in 2006 already, especially when Mark Saad confirmed to me that 6 Celutions were delivered to the clinics appointed by Olympus. The manufacturing deal never made economic sense and the fact that Cytori only have to re-pay mini-sums to Olympus to get out of the deal actually does not make sense either..... :cool: :cool: but we will get to that at a later point.

Key is this - from my article The mystery application- Fistula after Crohn´s

At the very early beginning of the Cytori/Olympus business relationship-that is soon after Cytori closed its manufacturing agreement with Olympus in November 2005- it became clear to me, after studyinolympus-hdtv endo picg the details of that particular agreement, that the agreement didnt make economic sense for Olympus and that an alterior motive HAD to exist in order for them to close that deal. That motive "revealed" itself shortly thereafter, when in February 2006 Cytori provided Olympus the option for first rights of partner deal negotiations on an "undisclosed therapeutic application" in return for a payment of 1,5Mio$. Obviously Olympus intended to enter the field of THERAPEUTIC regenerative medicine synergistic to their main competency- the field of gastroenterology- where they are global market leader in endoscopy with a 75% market share.
The deal was not just "a right to negotiate" but a little bit more....that is Olympus received SIX Celutions at locations of their choice to conduct a feasibility clinic, which you can read in the two page excerpt from an appendix to the 10Q of the 2006 first quarter. pdfolympus-first-right-2006.pdf48.91 KB22/06/2012, 16:32
Obviously Olympus wanted to take the "safe route" and not leave the engineering of the core business device to a small group of "talented" molecular biologists, but take it in their ownpipeline early 2007 competent engineering hands. Anyway- the following slide was presented by Calhoun at the Stem Cell Summit in San Diego in February 2007- under the heading "gastro-intestinal. Fistulae was in clinical investigation and the immune disorder Crohn´s itself in pre-clinical investigation. This was confirmed a few times by "editing mishaps" in several 10Qs, when fistulae was mentioned instead of "undisclosed" application, when describing Olympus´rights from this deal. Of course- a deal was never made (at least as of today June 24 2012). On the other side Cytori never picked up the 50% of the development cost for Celution One from the JV (estimated north of 50 Mio$). One can assume some compensation being done here. Some more confirmation of the ongoing trial was noted again late 2008, but silence untill approval was received as indicated in the introduction to this article. Approval was announced on July 27, 2010 and considering that never clinical data were presented on the app and the foregoing write-up, there can hardly be any doubt in respect of the identity of the third party owning this data- Olympus of course.
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.103 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites